CAM
ALBO

Cormorant Asset Management’s Albireo Pharma Inc ALBO Stock Holding History

Cormorant Asset Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500,000
Closed -$17.6M – 129
2021
Q1 		$17.6M Hold
500,000
– – 0.39% 57
2020
Q4 		$18.8M Sell
500,000
-200,000
-29% -$7.27M 0.45% 51
2020
Q3 		$23.4M Buy
+700,000
New +$20.4M 0.9% 35

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Cormorant Asset Management's ALBO Position: Q2 2021 in Review

Cormorant Asset Management sold out of Albireo Pharma Inc (ALBO) in Q2 2021, closing a stake of 500,000 shares — an estimated $17.6M sold.

Cormorant Asset Management first reported a position in ALBO in Q3 2020 and held it in 3 quarters. The position peaked at $23.4M in Q3 2020. 99 funds tracked by Wall St. Rank hold ALBO as of Q2 2021.

  • Cormorant Asset Management reported no remaining Albireo Pharma Inc position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 500,000 Albireo Pharma Inc shares in Q2 2021, an estimated $17.6M.
  • Cormorant Asset Management first reported a position in Albireo Pharma Inc in Q3 2020 and held it in 3 quarters.
  • Cormorant Asset Management's Albireo Pharma Inc position peaked at $23.4M in Q3 2020.
  • 99 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.